In our efforts to discover novel and reliable therapeutic targets in OSA, we have identified Chondroitin Sulfate proteoglycan 4 (CSPG4) as a promising candidate involved in OSA malignancy. Here, CSPG4 is linked to obstructive sleep apnea syndrome.